Zoetis, the world’s leading animal health company, has announced that it will expand its portfolio of products and services for horses with the Stablelab®hand-held, point-of-care diagnostic blood test, which provides veterinarians critical information related to equine inflammation in 10 minutes.
Woman caring for horse
The Stablelab hand-held reader expands point-of-care diagnostic offerings to deliver more comprehensive equine health care by providing a stall-side blood testThe Stablelab hand-held reader expands point-of-care diagnostic offerings to deliver more comprehensive equine health care by providing a stall-side blood test.
© 2016 by Tandem
The Stablelab hand-held reader detects and quantifies the biomarker Serum Amyloid A (SAA), which is a major, acute phase protein produced by the liver that rapidly and dramatically increases in response to inflammation caused by infection. By measuring SAA, veterinarians can assess the severity of an infection sooner – often, before clinical symptoms start – and able to monitor the horse’s response over the course of treatment.1
“Zoetis has always been committed to providing veterinarians and horse owners with new and enhanced solutions to better predict, prevent, detect and treat disease in the animals under their care,” said Jeannie Jeffery, Business Unit Head, U.S. Equine for Zoetis.
“The Stablelab test kit broadens our equine offerings with convenient stall-side testing for quickly and accurately detecting a reliable indicator of infection in horses. Point-of-care testing is one of the fastest-growing areas of diagnostics and this test is rapidly becoming a standard of care in equine practice.”
Jeffery added that SAA provides the most accurate biomarker of inflammation caused by infection allowing practitioners a means to monitor response to treatment over time.
Stablelab joins the Zoetis Diagnostics portfolio which features the VetScan®, Alinity (i-STAT) and other point of care diagnostic product lines. These products complement the range of equine health offerings from Zoetis and align with the company’s focus on health and wellness as part of the continuum of animal care.
Zoetis will manufacture, market and distribute the commercially available Stablelab products. For immediate needs, veterinarians should continue to order through their preferred distributor and contact Stablelab directly for any product related questions at hello@stablelab.com. For more information about Stablelab, please visit www.stablelab.com.
About Zoetis
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and a range of services.
Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2018, the company generated annual revenue of $5.8 billion with approximately 10,000 employees. For more information, visit www.zoetisus.com.
1. Viner M, Mazan M, Bedenice D et al. Comparison of Serum Amyloid A in Horses with Infectious and Non-Infectious Respiratory Diseases. J of Equine Vet Sci. 49 (2017) 11-13.
Press release provided by Zoetis